1. Forty years of Tuberculous meningitis: The new face of an old enemy
- Author
-
I. Corral-Corral, Andrea García-Caballero, M.J. López-Martinez, M. Tato-Diez, Rafael Cantón, Laura B. Martínez-García, C. Navarro-San Francisco, and E Gómez-Mampaso
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,Pediatrics ,medicine.medical_specialty ,Tuberculosis ,medicine.medical_treatment ,030106 microbiology ,Age at diagnosis ,HIV Infections ,Permanent disability ,Spinal Puncture ,Tuberculous meningitis ,lcsh:Infectious and parasitic diseases ,Time-to-Treatment ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,Meningitis ,lcsh:RC109-216 ,030212 general & internal medicine ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Immunosuppression ,General Medicine ,Nucleic acid amplification tests ,Middle Aged ,medicine.disease ,Adenosine deaminase ,Infectious Diseases ,Spain ,Tuberculosis, Meningeal ,Female ,business - Abstract
Background: Tuberculous meningitis (TBM) occurs in 1–5% of cases of tuberculosis. Without early treatment, mortality and permanent disability rates are high. Methods: A retrospective study performed at a tertiary hospital in Madrid (Spain) to describe clinical, diagnostic, and therapeutic aspects of TBM and analyze epidemiological trends over forty years, divided into two intervals (1979−1998 and 1999−2018). Results: Overall, TBM was diagnosed in 65 patients (1.8% of new tuberculosis diagnoses), 48 in the first period and 17 in the second one. Median age at diagnosis increased from 38.5 to 77 years (p = 0.003). The proportion of non-HIV immunosuppressed patients increased (from 2.1% to 29.4%, p < 0.001), while the percentage of patients with a history of drug-abuse decreased (from 33.3% to 5.9%, p = 0.027). The median time between the onset of neurological symptoms and lumbar puncture increased from seven to 15 days (p = 0.040). The time between the onset of symptoms and the initiation of tuberculostatic treatment also increased from eleven to 18 days (p = 0.555). Results from image, biochemical, and microbiological tests showed no differences between both periods. A decreasing trend was observed in survival rates at 1-week (from 97.9% to 64.7%, p < 0.001), 1-month (from 91.7% to 58.8%, p = 0.002) and 1-year (from 85.4% to 47.1%, p = 0.002) after TBM diagnosis. Conclusions: The profile of patients diagnosed with TBM has changed from a young HIV-infected patient with a history of drug addiction to an elderly patient with non-HIV immunosuppression. Diagnosis and start of treatment both experienced a noticeable delay in the second period, which could help explain the increase in mortality observed across the two periods.
- Published
- 2020
- Full Text
- View/download PDF